Denub 60mg Injection contains the active ingredient Denosumab, which is used to treat osteoporosis, a condition where bones become weakened and brittle. It is also prescribed to help prevent bone complications in patients with certain cancers, such as multiple myeloma and bone metastases.
Denub works by inhibiting a protein called RANK ligand, which plays a role in the breakdown of bone tissue. By blocking this protein, Denub helps increase bone density and reduce the risk of fractures, particularly in postmenopausal women with osteoporosis and in cancer patients experiencing bone loss related to their condition. Patients with moderate renal impairment may need close monitoring of kidney function during treatment.
Adequate calcium and vitamin D supplementation is essential during treatment with Denub. The medication should not be used in individuals with known hypersensitivity or allergic reactions to any of its components. Denub is not approved for use in children or adolescents, as its safety and effectiveness in individuals under 18 years old have not been established. Caution is also advised when using Denub in individuals with pre-existing hypoparathyroidism (low parathyroid hormone levels).
Patients should discuss their medical history with their healthcare provider to ensure Denub is suitable for their condition